New research suggests that /鈥檚 mRNA Covid-19 vaccine, BNT162b2, protects against two variants of SARS-CoV-2, the virus that causes Covid-19, that have emerged in the UK and South Africa.
The research, which has been published on , was carried out by Pfizer in collaboration with scientists from the University of Texas Medical Branch.
The two variants, which are believed to be responsible for escalating Covid-19 crises in the UK and elsewhere, share a mutation in the spike protein called N501Y. They are also characterised by other, different viral mutations.
The researchers carried out lab tests on the serum of 20 participants of Pfizer鈥檚 Covid-19 vaccine trial and found that BNT162b2 successfully neutralised SARS-CoV-2 viruses engineered to contain the same N501Y mutation as the circulating variants.
The study also showed that BNT162b2-elicited human sera cause preserved neutralisation of 15 other mutations of SARS-CoV-2 that are currently circulating.
The researchers behind the study warned that these findings should be viewed with caution, not only because the paper is yet to be peer-reviewed but also because the engineered virus they relied upon did not include a full set of the spike mutations found in either the UK or South African viral strains. There is particular concern about the E484K mutation found in the South African variant.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataLondon Metropolitan University professor of molecular immunology Gary McLean said: 鈥淚t鈥檚 good news, but not surprising. The limitation is that [the study] did not construct SARS-CoV-2 with the full set of spike mutations in the UK variant and therefore further conclusions cannot be made fully at this stage.鈥�
Pfizer and the University of Texas will continue to monitor BNT162b2鈥檚 efficacy against the other mutations found in the UK and South African variants, as well as other emerging viral mutations and strains.”
Pfizer chief scientific officer of viral vaccines Philip Dormitzer, who is one of the authors of the study, told : 鈥淪o we鈥檝e now tested 16 different mutations, and none of them have really had any significant impact. That鈥檚 the good news. That doesn鈥檛 mean that the 17th won鈥檛.鈥�
Researchers at the UK鈥檚 Porton Down laboratory are also seeking to determine if either the UK or South African variants of SARS-CoV-2 could make the /Oxford or Pfizer/BioNTech approved vaccines less effective.
UK regulators recently approved a third Covid-19 vaccine, COVID-19 Vaccine , for temporary and emergency use in adults.
